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Abstract
Background: Development of new treatments for Alzheimer’s disease (AD) has broadened into early interventions
in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer’s Disease
Assessment Scale–Cognitive subscale (ADAS-Cog) was originally developed to measure cognition in patients with
mild to moderate AD. Attempts to improve its properties for early AD by removing items prone to ceiling and/or
by adding cognitive measures known to be impaired early have yielded a number of ADAS-Cog variants. Using
Alzheimer’s Disease Neuroimaging Initiative data, we compared the performance of the 3-, 5-, 11- and 13-item
ADAS-Cog variants in subjects with early AD. Given the interest in enrichment strategies, we also examined this
aspect with a focus on cerebrospinal fluid (CSF) markers.
Methods: Subjects with mild cognitive impairment (MCI) and mild AD with available ADAS-Cog 13 and CSF data
were analysed. The decline over time was defined by change from baseline. Direct cross-comparison of the ADAS-Cog
variants was performed using the signal-to-noise ratio (SNR), with higher values reflecting increased sensitivity to detect
change over time.
Results: The decline over time on any of the ADAS-Cog variants was minimal in subjects with MCI. Approximately half
of subjects with MCI fulfilled enrichment criteria for positive AD pathology. The impact of enrichment was detectable
but subtle in MCI. The annual decline in mild AD was more pronounced but still modest. More than 90 % of subjects
with mild AD had positive AD pathology. SNRs were low in MCI but greater in mild AD. The numerically largest SNRs
were seen for the ADAS-Cog 5 in MCI and for both the 5- and 13-item ADAS-Cog variants in mild AD, although
associated confidence intervals were large.
Conclusions: The possible value of ADAS-Cog expansion or reduction is less than compelling, particularly in MCI. In
mild AD, adding items known to be impaired at early stages seems to provide more benefit than removing items on
which subjects score close to ceiling.
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Background
For the past two decades, the 11-item Alzheimer’s Dis-
ease Assessment Scale–Cognitive subscale (ADAS-Cog
11) has been a nearly ubiquitous measure of cognition in
clinical trials of putative new therapies for Alzheimer’s
disease (AD). However, recent use of this scale has re-
vealed a number of limitations driven by a shift toward
assessing and treating patients in earlier stages of the
disease. One is the lack of sensitivity to detect change in
early stages of AD, as it seems most sensitive when used
in patients in the moderate stage of AD [i.e., Mini Men-
tal State Examination (MMSE) score of 12–18] [1]. The
second relates to measuring cognitive domains known to
be impaired at the early stages, such as executive func-
tion [2–4], that are not captured by ADAS-Cog 11. As a
result, subjects with mild cognitive impairment (MCI)
tend to score at ceiling (i.e., score of 0 for ADAS-Cog)
on eight of the 11 ADAS-Cog subtest items [5–7].
In response to criticism of the ADAS-Cog’s inability to
measure relevant cognitive domains, Mohs et al. [8] sug-
gested the use of additional tests, such as Digit
Cancellation, Delayed Word Recall and a Maze test. This
has led to the creation of ADAS-Cog variants such as
the ADAS-Cog 13. A second approach to improving the
scale’s sensitivity was to remove subtests prone to ceiling
effects (i.e., ADAS-Cog 3). ADAS-Cog 3 tests solely
memory, however. The ADAS-Cog 5 variant combines
the ADAS-Cog 3 items with Delayed Recall and Digit
Cancellation from ADAS-Cog 13. This tactic could im-
prove detection of cognitive decline over time because it
measures more relevant domains impacted in early stages
of the disease than the ADAS-Cog 3. However, the sensi-
tivities of these new variants to detect change over time
have not been compared in patients with early AD.
In this study, we employed data from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database to ad-
dress this issue, as described in the Methods section.
Our aim was to evaluate which of the four variants
(ADAS-Cog 3, ADAS-Cog 5, the original ADAS-Cog 11,
and ADAS-Cog 13) best detects cognitive decline over
time in subjects with MCI or mild AD. We hypothesised
that the ‘tailored’ ADAS-Cog 5 variant would provide
the best means of assessing decline in the subjects with
early AD compared with the other variants. It should be
noted that our goal was not to validate a new instru-
ment. In addition, as enrichment should help to identify
subjects with MCI with AD pathology [9–11], we evalu-
ated whether it helps to improve the sensitivity of the
ADAS-Cog variants to detect decline over time.
Methods
Data source1
Data used in the preparation of this article were obtained
from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database (adni.loni.usc.edu). The ADNI was
launched in 2003 by the National Institute on Aging
(NIA), the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), the Food and Drug Administration
(FDA), private pharmaceutical companies and non-profit
organizations, as a $60 million, 5-year public private part-
nership. The primary goal of ADNI has been to test
whether serial magnetic resonance imaging (MRI), positron
emission tomography (PET), other biological markers, and
clinical and neuropsychological assessment can be com-
bined to measure the progression of mild cognitive impair-
ment (MCI) and early Alzheimer’s disease (AD).
Determination of sensitive and specific markers of very
early AD progression is intended to aid researchers and cli-
nicians to develop new treatments and monitor their effect-
iveness, as well as lessen the time and cost of clinical trials.
The Principal Investigator of this initiative is Michael
W. Weiner, MD, VA Medical Center and University of
California–San Francisco. ADNI is the result of efforts of
many coinvestigators from a broad range of academic in-
stitutions and private corporations, and subjects have been
recruited from over 50 sites across the U.S. and Canada.
The initial goal of ADNI was to recruit 800 subjects but
ADNI has been followed by ADNI-GO and ADNI-2.
To date these three protocols have recruited over 1500
adults, ages 55 to 90, to participate in the research, con-
sisting of cognitively normal older individuals, people
with early or late MCI, and people with early AD. The
follow up duration of each group is specified in the proto-
cols for ADNI-1, ADNI-2 and ADNI-GO. Subjects origin-
ally recruited for ADNI-1 and ADNI-GO had the option
to be followed in ADNI-2. For up-to-date information,
see www.adni-info.org.
Trial registration details
The trial is registered at ClinicalTrials.gov under trial
registration numbers NCT00106899 (date of registration
31 March 2005), NCT01231971 (date of registration 27
October 2010) and NCT01078636 (date of registration 1
March 2010).
Data from ADNI 1, ADNI Grand Opportunities
(ADNI GO) and ADNI 2 were downloaded on 30 Sep-
tember 2014. Subjects with available ADAS-Cog 13 data
(i.e., comprising ADAS-Cog 11 items plus Delayed Word
Recall and Digit Cancellation) and with available base-
line cerebrospinal fluid (CSF) biomarkers, both amyloid-
β (Aβ) and total Tau (t-Tau), were included in the main
analysis of subjects with mild AD or MCI.
Due to the variable amount of available data at later
time points, our focus was on subjects with change from
baseline to 12 months in mild AD and to 24 months in
MCI. Data beyond 12 months for mild AD and beyond
24 months for MCI were considered for data description
over time.
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Ethics, consent and permissions
The ADNI study was approved individually by the insti-
tutional review boards of all the participating institu-
tions. Written informed consent was obtained from all
participants at each site. Please see the Acknowledge-
ments section for a list of institutional review boards
that approved the study.
Study participants
The general inclusion and exclusion criteria for the
ADNI study and the screening procedures were de-
scribed by Petersen et al. [12]. The original subject co-
horts included age-matched cognitively healthy subjects,
subjects with MCI and subjects with mild AD dementia.
The subjects with MCI had MMSE scores of 24–30 and
a Clinical Dementia Rating (CDR) global score of 0.5
with a mandatory requirement of the memory box score
being 0.5 or greater. The subjects with MCI had to be
largely intact with regard to functional performance and
could not qualify for the diagnosis of dementia [13]. The
subjects with mild AD had MMSE scores of 20–26, a
CDR score 0.5 or 1 and met the National Institute of
Neurological and Communicative Disorders and Stroke/
Alzheimer’s Disease and Related Disorders Association
criteria for probable AD [14]. Subjects with MCI and
subjects with mild AD were also required to meet cri-
teria for memory impairment on the Wechsler Memory
Scale–Revised Logical Memory II subscale [12].
Populations in the statistical assessment
The ‘MCI set’ comprised subjects with MCI with avail-
able ADAS-Cog 13 at baseline and 24 months as well as
available baseline Aβ and t-Tau CSF biomarkers. The
‘AD set’ comprised subjects with mild AD with available
ADAS-Cog 13 at baseline and 12 months as well as
available baseline Aβ and t-Tau CSF biomarkers. The
MCI and AD sets described above are referred to as
‘non-enriched’ because their clinical data were analysed
regardless of their biomarker status. The ‘biomarker-posi-
tive sets’ (‘enriched’) comprised those subjects with a posi-
tive AD pathology as defined by the magnitude of selected
baseline CSF biomarkers [15] or with the presence of a
genetic risk marker apolipoprotein E ε4 (ApoE4):
 CSF t-Tau/Aβ ratio >0.39
 CSF Aβ1–42 < 192 pg/ml
 CSF phosphorylated Tau (p-Tau) >23 pg/ml
 CSF t-Tau >93 pg/ml
 ApoE4 risk (one or two copies of the ApoE4 allele)
For the purposes of this article, a CSF t-Tau/Aβ ratio
>0.39 was considered to be the main enrichment strat-
egy because, in the context of MCI, this would fulfil the
recent International Working Group 2 research criteria
for prodromal AD [16]. These cohorts are labelled as
MCI+ and AD+ in this publication.
The ‘biomarker-negative’ sets comprised the comple-
mentary groups that did not fulfil the baseline biomarker
enrichment criteria for AD based on t-Tau/Aβ and thus
were not classified as having prodromal AD. Only
biomarker-negative subjects with MCI are presented
(MCI−). There were very few biomarker-negative sub-
jects with mild AD.
Statistical methods
In this study, we compared the ADAS-Cog 3 [17],
ADAS-Cog 13 [8], the traditional ADAS-Cog 11 [18, 19]
and the ADAS-Cog 5 variants (Additional file 1) to see
which of them had the best ability to demonstrate a
change in subjects with mild AD or with MCI.
Values for ADAS-Cog total scores were calculated on
the basis of individual items and were recorded as miss-
ing if at least one ADAS-Cog item was not available (af-
fecting six subjects with MCI and seven with mild AD).
CSF measurements were obtained from biomarker data-
sets, where the latest available recorded result of the
baseline sample was selected in case of duplicates.
Change from baseline was calculated for each individ-
ual. The mean change from baseline was calculated by
cohort for the MCI and mild AD sets, as well as for the
individual enriched sets, to describe the decline over
time.
Demographics were obtained at the baseline visit and
described by their mean value and standard deviation
for continuous variables or by percentage for categorical
variables.
Sensitivity of the ADAS-Cog variants to show a
change over time was assessed using the signal-to-noise
ratio (SNR). The SNR is calculated as the estimated
mean change from baseline divided by the correspond-
ing standard deviation. A positive or negative number
indicates the direction of change towards increase (wors-
ening) or reduction (improvement) from the observed
ADAS-Cog score at baseline. The SNR reflects changes
in the outcome relative to its variability, thereby allowing
for direct comparison of different ADAS-Cog variants
with respect to their sensitivity to detect a change from
baseline. An increased SNR, representing a higher sensi-
tivity, might be expected after removal of items that
affect the mean change from baseline minimally (e.g.,
consistently scoring at the ceiling) through an antici-
pated decrease in variability that should be associated
with a total score containing fewer individual items.
The mean change in ADAS-Cog score and the stand-
ard deviation were estimated from an analysis of covari-
ance model correcting for baseline ADAS-Cog and
MMSE scores, age, sex and ApoE4 risk category. Vari-
ability of SNR estimates was captured using 95 %
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bootstrap confidence intervals based on 1000 samples
for each set.
The four different ADAS-Cog variants were compared
using a hypothetical patient, which was an ApoE4-positive
75-year-old woman with baseline MMSE and ADAS-Cog
scores in line with the diagnostic group. Specifically, for
subjects with MCI, the estimated baseline MMSE of 28
and ADAS-Cog 11 score of 10 were used. For subjects
with mild AD, a baseline MMSE of 23 and ADAS-Cog 11
score of 18 were assumed. The baseline ADAS-Cog score
for the remaining ADAS-Cog variants was estimated from
a linear regression of baseline values of the respective
ADAS-Cog variant vs. baseline ADAS-Cog 11.
Differences in SNR between pairs of ADAS-Cog vari-
ants were assessed by means of p values obtained from a
paired t test accounting for correlated data, making use of
covariance estimates obtained from the aforementioned
bootstrapping samples. The reported p values are not cor-
rected for multiplicity and are considered exploratory.
The analyses described above were performed on
ADAS-Cog variants for the group of enriched subjects
and separately for the group of non-enriched subjects.
No imputations for missing data or for discontinued
subjects were performed; subjects with missing informa-
tion were excluded from the analysis.
Results
Datasets analysed
There were 634 subjects with MCI for whom all baseline
and month 24 ADAS-Cog 13 values were available. Of
these, 382 (60 %) provided a CSF sample at baseline. Of
the 242 subjects with mild AD for whom all baseline and
month 12 ADAS-Cog 13 values were available, 97 (40 %)
provided a CSF sample at baseline. The 229 subjects with
MCI and 73 with mild AD who did not have ADAS-Cog
13 values at 24 or 12 months, respectively, were not in-
cluded in the analyses. The number of subjects attending
follow-up visits diminished over time. To maintain a suffi-
cient number of subjects in the analyses, the focus was on
change from baseline to 12 months in mild AD, while the
change to 24 months was analysed for subjects diagnosed
with MCI.
Baseline characteristics
The baseline characteristics in the MCI and mild AD co-
horts were similar, except that subjects with mild AD
were older and more cognitively impaired (Table 1).
The 206 MCI+ (t-Tau/Aβ >0.39) set had baseline
demographic characteristics similar to those of the non-
enriched set, with the exception that 69 % of MCI+ sub-
jects were ApoE4-positive vs. only 20 % of MCI− sub-
jects. The baseline MMSE and CDR scores were also
similar between the groups. The MCI+ set, however, was
more impaired on those ADAS-Cog variants which in-
clude the additional measures of Delayed Word Recall
and Digit Cancellation (e.g., ADAS-Cog 13 and the ‘tai-
lored’ ADAS-Cog 5). The data in mild AD and mild AD
+ sets are almost identical, as the majority of subjects
with mild AD enrolled in ADNI studies had positive AD
pathology at baseline (>90 %).
Performance of ADAS-Cog variants in MCI and mild AD
populations with and without enrichment
As expected, the magnitude of the absolute change on
ADAS-Cog in mild AD is larger than that in MCI. As
shown in Table 2, there was practically no decline in
Table 1 Demographic and clinical data at baseline
MCI MCI+ MCI− Mild AD Mild AD+
Number of subjects (100 %) 382 206 176 97 90
Female (%) 43 % 42 % 45 % 45 % 48 %
Caucasian, n (%) 94 % 97 % 90 % 96 % 96 %
Age, yr 71.97 ± 7.39 72.97 ± 7.10 70.80 ± 7.56 75.17 ± 7.70 74.85 ± 7.66
Education, yr 16.28 ± 2.59 16.31 ± 2.62 16.25 ± 2.55 15.52 ± 2.60 15.51 ± 2.58
ApoE4 at risk,a n (%) 177 (46 %) 142 (69 %) 35 (20 %) 67 (69 %) 65 (72 %)
MMSE 27.85 ± 1.75 27.41 ± 1.82 28.37 ± 1.52 23.19 ± 1.99 23.14 ± 1.99
CDR global 0.50 ± 0.00 0.50 ± 0.00 0.50 ± 0.00 0.77 ± 0.28 0.77 ± 0.28
CDR-SB 1.40 ± 0.84 1.56 ± 0.92 1.21 ± 0.70 4.40 ± 1.71 4.41 ± 1.65
ADAS-Cog 11 9.50 ± 4.29 10.83 ± 4.46 7.94 ± 3.50 19.66 ± 6.30 20.14 ± 6.26
ADAS-Cog 3 8.23 ± 3.76 9.43 ± 3.92 6.82 ± 3.02 15.95 ± 4.15 16.28 ± 4.12
ADAS-Cog 5 13.96 ± 6.17 16.12 ± 6.28 11.43 ± 4.99 26.20 ± 5.31 26.62 ± 5.23
ADAS-Cog 13 15.23 ± 6.68 17.52 ± 6.81 12.55 ± 5.43 29.91 ± 7.44 30.52 ± 7.35
Aβ amyloid-β, AD Alzheimer’s disease, ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, ApoE4, apolipoprotein E ε4, CDR Clinical Dementia
Rating, MCI mild cognitive impairment, MMSE Mini Mental State Examination, SB Sum of Boxes
Populations enriched based on t- Tau/Aβ ratio are labelled as MCI+ and AD+. Data are presented as mean ± standard deviation unless indicated otherwise
aApoE4 status is not available for one subject in the MCI group
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mean ADAS-Cog 11 score in subjects with MCI (wors-
ening of 0.9 on a 70-point scale over 24 months and 1.9
points over 36 months). The change from baseline was
modest in patients with mild AD (worsening of 3.5
points over 12 months and of 8.3 points over 24 months)
(Additional file 2). This was also reflected on the MMSE
(Additional file 3).
On ADAS-Cog 11, enrichment minimally increased
the decline in subjects with MCI over 24 months
(Table 2). Even after 36 months in MCI+ subjects,
the decline on ADAS-Cog 11 was less than 4 points.
As shown in Table 3, there was a minimal decline
over 24 months and a minimal impact of enrichment
on the other ADAS-Cog variants (3-, 5- and 13-item)
in subjects with MCI. As expected, there was no
change in any of the ADAS-Cog variants in the sub-
jects with MCI without AD pathology (MCI−) up to
36 months.
Changes over time on other ADAS-Cog variants were
modest (4.35 points over 12 months on ADAS-Cog 13)
in subjects with mild AD (Table 4). Even though the
number of subjects with mild AD attending a visit at
24 months was low, there was a trend toward a larger
decline over 24 months with almost a 10-point decline
on ADAS-Cog 13.
As the majority of subjects with mild AD had posi-
tive AD pathology at baseline (>90 %), no benefit of
enrichment could be detected with respect to the in-
creased magnitude of change over time (Additional
file 2). Analysis of the contribution of individual items
showed that Word Recall (Q1), Delayed Word Recall
(Q4) and Word Recognition (Q8) largely contributed
to the overall ADAS-Cog score (Fig. 1). Delayed
Word Recall was impaired early and contributed
largely to the overall score of the ADAS-Cog variants
containing this item (i.e., the 13- and 5-item variants).
Thus, somewhat counterintuitively, the score of the
ADAS-Cog 5 exceeded that of the ADAS-Cog 11,
presumably due to the contribution of Delayed Word
Recall.
Comparison of ADAS-Cog variants in MCI and mild AD
populations with and without enrichment using SNR
To account for differences in possible maximum range
and the variability in change from baseline, and hence to
allow for cross-comparison of the various ADAS-Cog
variants, SNRs were estimated on the basis of an analysis
of covariance approach, correcting for baseline age,
baseline MMSE, sex and ApoE4 risk status. Specific
comparisons of estimated SNRs across ADAS-Cog vari-
ants were made for a hypothetical patient as described
in the Methods section. Table 5 shows the estimated
SNRs for subjects with MCI, jointly presented with the
corresponding bootstrap 95 % confidence intervals.
Similarly, Table 6 shows results for subjects diagnosed
with mild AD.
Higher SNR values reflect increased sensitivity to de-
tect a change. In subjects with MCI, SNRs based on esti-
mated change from baseline to 24 months ranged
between 0.37 and 0.61 (Table 5). The numerically largest
SNRs were seen for the enriched set with ApoE4 across
all variants, and when we compared across subject sets,
for the ADAS-Cog 5. However, the 95 % confidence in-
tervals were broad (e.g., 0.33–0.88 for ADAS-Cog 5 on
ApoE4+ set) and almost identical to ADAS-Cog 13 and
thus did not suggest that SNRs differed substantially
among the variants. Overall, estimated SNRs were rela-
tively similar, when looking at both different variants
and different enrichment strategies (Fig. 2). A more for-
mal comparison based on paired t tests was done (Add-
itional file 4).
For subjects with mild AD at the 12-month time
point, the estimated SNR values ranged from 0.81 to
1.16 (Table 6). Similarly to MCI, the numerically
highest SNRs were seen for the ApoE4-enriched set
across all variants. Across all subject sets, the highest
SNRs were seen for both the 5-item and 13-item vari-
ants. The highest SNR (1.16) was observed in the
ApoE4-enriched set on ADAS-Cog 13. The 95 % con-
fidence intervals were also broad and overlapping in
mild AD.
Table 2 ADAS-Cog 11 scores at each visit and change from baseline for MCI patients
MCI (non-enriched) MCI+ (enriched) MCI− (‘biomarker-negative’)
Number of
subjects
ADAS-Cog 11 CFB Number of
subjects
ADAS-Cog 11 CFB Number of
subjects
ADAS-Cog 11 CFB
Baseline/screen 382 9.5 ± 4.29 206 10.83 ± 4.46 176 7.94 ± 3.49
Month 6 376 9.6 ± 4.75 0.0 ± 3.40 204 11.16 ± 4.82 0.3 ± 3.61 172 7.70 ± 3.91 −0.31 ± 3.10
Month 12 380 9.3 ± 5.23 −0.2 ± 3.68 206 11.08 ± 5.54 0.3 ± 4.06 174 7.27 ± 3.95 −0.68 ± 3.10
Month 24 382 10.4 ± 6.40 0.9 ± 4.45 206 12.74 ± 6.87 1.9 ± 4.92 176 7.70 ± 4.48 −0.24 ± 3.51
Month 36 169 10.8 ± 7.06 1.9 ± 5.45 89 13.83 ± 7.86 3.7 ± 6.21 80 7.40 ± 3.90 −0.26 ± 3.41
ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, CFB change from baseline, MCI mild cognitive impairment
Increased score on ADAS-Cog 11 (maximum total score 70) indicates cognitive worsening. Data are presented as mean ± SD
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Table 3 ADAS-Cog scores and change from baseline up to 36 months for patients with MCI
ADAS-Cog 3 ADAS-Cog 5 ADAS-Cog 13
Number of subjects Score CFB Number of subjects Score CFB Number of subjects Score CFB
MCI (non-enriched)
Baseline/screen 382 8.23 ± 3.76 382 13.96 ± 6.17 382 15.23 ± 6.68
Month 6 376 8.30 ± 4.14 0.01 ± 2.99 375 14.00 ± 6.68 −0.07 ± 4.01 375 15.28 ± 7.25 −0.07 ± 4.37
Month 12 381 8.09 ± 4.42 −0.15 ± 3.09 380 13.72 ± 7.09 −0.23 ± 3.95 379 14.97 ± 7.83 −0.24 ± 4.49
Month 24 382 8.94 ± 5.23 0.71 ± 3.56 382 15.09 ± 8.30 1.13 ± 4.87 382 16.57 ± 9.41 1.34 ± 5.68
Month 36 169 9.02 ± 5.34 1.23 ± 4.00 168 15.11 ± 8.58 1.95 ± 5.58 168 16.89 ± 10.18 2.59 ± 6.89
MCI+ (enriched)
Baseline/screen 206 9.43 ± 3.92 206 16.12 ± 6.28 206 17.52 ± 6.81
Month 6 204 9.71 ± 4.28 0.23 ± 3.17 203 16.38 ± 6.75 0.14 ± 4.18 203 17.84 ± 7.22 0.19 ± 4.56
Month 12 206 9.57 ± 4.63 0.14 ± 3.43 205 16.24 ± 7.21 0.16 ± 4.10 205 17.75 ± 8.01 0.28 ± 4.69
Month 24 206 10.91 ± 5.42 1.48 ± 3.78 206 18.32 ± 8.49 2.21 ± 5.20 206 20.15 ± 9.85 2.63 ± 6.24
Month 36 89 11.37 ± 5.72 2.55 ± 4.40 89 18.96 ± 9.00 3.82 ± 6.03 89 21.42 ± 11.01 5.02 ± 7.60
MCI− (biomarker − negative)
Baseline/screen 176 6.82 ± 3.02 176 17.52 ± 6.81 176 12.55 ± 5.43
Month 6 172 6.62 ± 3.25 −0.24 ± 2.75 172 17.84 ± 7.22 −0.31 ± 3.79 172 12.26 ± 6.03 −0.38 ± 4.12
Month 12 175 6.35 ± 3.45 −0.50 ± 2.69 175 17.75 ± 8.01 −0.68 ± 3.73 174 11.69 ± 6.20 −0.85 ± 4.18
Month 24 176 6.63 ± 3.88 −0.19 ± 3.06 176 20.15 ± 9.85 −0.11 ± 4.12 176 12.37 ± 6.80 −0.18 ± 4.51
Month 36 80 6.40 ± 3.35 −0.25 ± 2.88 79 21.42 ± 11.01 −0.16 ± 4.15 79 11.78 ± 5.95 −0.15 ± 4.69
ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, CFB change from baseline, MCI mild cognitive impairment














Table 4 ADAS-Cog score and change from baseline up to 24 months for subjects with mild AD
ADAS-Cog 3 ADAS-Cog 5 ADAS-Cog 13
Number of subjects Score CFB Number of subjects Score CFB Number of subjects Score CFB
Mild AD (non-enriched)
Baseline/screen 97 15.95 ± 4.15 97 26.20 ± 5.31 97 29.91 ± 7.44
Month 6 95 16.95 ± 4.83 1.10 ± 3.85 95 27.62 ± 6.25 1.52 ± 4.32 95 31.86 ± 8.51 2.10 ± 4.79
Month 12 97 17.77 ± 5.29 1.82 ± 3.91 97 28.84 ± 6.75 2.64 ± 4.39 97 34.26 ± 10.43 4.35 ± 5.89
Month 24 40 18.68 ± 5.82 3.81 ± 5.12 40 30.27 ± 7.20 5.48 ± 6.13 38 37.17 ± 12.38 9.46 ± 9.15
Mild AD+ (enriched)
Baseline/screen 90 16.24 ± 4.12 90 26.62 ± 5.23 90 30.52 ± 7.35
Month 6 88 17.17 ± 4.89 1.03 ± 3.92 88 27.92 ± 6.32 1.41 ± 4.37 88 32.36 ± 8.58 1.99 ± 4.84
Month 12 90 18.19 ± 5.17 1.96 ± 3.98 90 29.42 ± 6.59 2.80 ± 4.46 90 35.08 ± 10.34 4.57 ± 6.03
Month 24 37 19.15 ± 5.77 4.06 ± 5.23 35 30.79 ± 7.18 5.63 ± 6.34 35 37.99 ± 12.51 9.77 ± 9.40
AD Alzheimer’s disease, ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, CFB change from baseline














SNRs are graphically displayed in Fig. 2. SNRs in mild
AD (Fig. 2, right panel) were larger than in subjects with
MCI (Fig. 2, left panel), indicating that all ADAS-Cog
variants are more sensitive to detect changes in subjects
with mild AD than in subjects with MCI. SNRs of the
variants fall within the 95 % bootstrap confidence inter-
vals of the ADAS-Cog 11 (Fig. 2, shaded area).
A more formal comparison of pairs of variants was done
based on t statistics for the difference in SNRs. Resulting p
values (corrected not for multiplicity, but for correlation
between variants) are reported in Additional file 4: Table
S4. As usual, small p values indicate a higher chance of a
true difference between the particular variants.
Among the various MCI subsets, there is no evidence
indicating a difference in SNR between any of the
ADAS-Cog variants based on the available ADNI data.
All p values were larger than 0.10 for comparisons to
the original ADAS-Cog 11.




























































Fig. 1 Relative percentage contribution of individual items to total Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog) score at
baseline for mild cognitive impairment population. a ADAS-Cog 3. b ADAS-Cog 5. c. ADAS-Cog 11. d ADAS-Cog 13
Table 5 Signal-to-noise ratio for change in ADAS-Cog variants over 24 months in MCI cohorts
ADAS-Cog 3 ADAS-Cog 5 ADAS-Cog 11 ADAS-Cog 13
SNR 95 % CI SNR 95 % CI SNR 95 % CI SNR 95 % CI
MCI 0.42 0.20–0.61 0.42 0.19–0.63 0.37 0.15–0.57 0.39 0.16–0.60
t-Tau/Aβ 0.43 0.15–0.69 0.45 0.16–0.73 0.39 0.11–0.65 0.42 0.12–0.69
Aβ 0.47 0.22–0.70 0.47 0.21–0.70 0.41 0.17–0.64 0.44 0.19–0.67
ApoE4+ 0.53 0.24–0.82 0.61 0.33–0.88 0.53 0.26–0.78 0.60 0.33–0.86
t-Tau 0.45 0.14–0.75 0.52 0.18–0.84 0.39 0.09–0.66 0.45 0.14–0.77
p-Tau 0.43 0.19–0.65 0.43 0.17–0.66 0.37 0.12–0.61 0.39 0.14–0.63
Aβ amyloid β, ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, ApoE4 apolipoprotein E ε4, CI confidence interval, MCI mild cognitive
impairment, MMSE Mini Mental State Examination, SNR signal-to-noise ratio
SNR estimates corrected for covariates, reported for an ApoE4-positive 75-year-old woman, baseline ADAS-Cog 11 of 10, baseline MMSE of 28. CIs were obtained
via bootstrapping
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In mild AD, the strongest evidence for a difference
based on p values (<0.10) was found when we compared
the 13- vs. 11-item and the 5- vs. 3-item variants for the
t-Tau- and p-Tau-enriched sets (Additional file 4). This
indicates that the difference between variants may be
driven by the two additional items (Delayed Word Recall
and Digit Cancellation) that are not included in the 3-
and 11-item variants. When the accepted enrichment
strategy of t-Tau/Aβ ratio was used, the p values were
above 0.10.
Discussion
ADAS-Cog has been the standard measure of cognition
in AD clinical trials [20], but recently conducted trials
with therapies aimed at slowing down disease progres-
sion in subjects at early stages of the disease revealed
the limited sensitivity of the original ADAS-Cog 11 to
detect change. Sensitivity to change may be compro-
mised by the lack of tests to assess cognitive domains
known to be impaired early in the disease, such as atten-
tion and executive functions [4], which has been ad-
dressed by adding tests to the original instrument [8]
(e.g., the ADAS-Cog 13). A second approach to improve
sensitivity of the instrument for early AD was to remove
items prone to ceiling effects (e.g., ADAS-Cog 3). Data
from subjects that score at ceiling inflate variance with
negligible benefits in measuring change over time or
treatment difference, particularly the possibility to detect
improvement in cognition. The ADAS-Cog 3 extracted
the items focused on memory (Word Recall, Orientation
and Word Recognition) that are among the earliest man-
ifestations of AD [4] and detect impairment in subjects
with MCI approximately midway between normal

















Reference subject: Female, APOE4+, Age = 75, MMSE = 23, ADAS11 = 18
CSF set Tau/Abeta
> 0.39
Abeta > 192 t-Tau > 93 p-Tau > 23APOE4 risk
















Reference subject: Female, APOE4+, Age = 75, MMSE = 28, ADAS11 = 10
CSF set Tau/Abeta
> 0.39
Abeta > 192 t-Tau > 93 p-Tau > 23APOE4 risk
Fig. 2 Signal-to-noise ratios (SNRs) for reference patients with mild cognitive impairment (MCI) and subjects with mild Alzheimer’s disease (AD).
SNRs were corrected for change from baseline (CFB) for reference patients with a MCI at 24 months and b mild AD at 12 months. Shaded area
represents bootstrap 95 % confidence intervals (CIs) of SNR for 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog11)
for each enrichment group. Bounds of CIs are connected solely for display purposes. Abeta amyloid-β, ApoE4 apolipoprotein E ε4, CSF cerebrospinal
fluid, p-Tau phosphorylated Tau, t-Tau total Tau, MMSE Mini Mental State Examination
Table 6 Signal-to-noise ratio for change in ADAS-Cog variants over 12 months in mild AD cohorts
ADAS-Cog 3 ADAS-Cog 5 ADAS-Cog 11 ADAS-Cog 13
SNR 95 % CI SNR 95 % CI SNR 95 % CI SNR 95 % CI
Mild AD 0.81 0.43–1.09 0.93 0.52–1.22 0.87 0.46–1.13 0.98 0.58–1.26
t-Tau/Aβ 0.83 0.41–1.10 0.95 0.53–1.23 0.86 0.46–1.12 0.96 0.55–1.24
Aβ 0.86 0.45–1.14 0.98 0.52–1.27 0.88 0.46–1.14 0.99 0.56–1.26
ApoE+ 0.87 0.37–1.20 1.01 0.50–1.35 1.05 0.56–1.36 1.16 0.66–1.50
t-Tau 0.89 0.38–1.21 1.13 0.55–1.46 0.86 0.39–1.16 1.04 0.49–1.35
p-Tau 0.82 0.42–1.10 0.96 0.50–1.24 0.87 0.46–1.16 0.99 0.58–1.27
Aβ amyloid β; AD Alzheimer’s disease, ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, CI confidence interval, MMSE Mini Mental State
Examination, SNR signal-to-noise ratio
SNR estimates corrected for covariates, reported for an ApoE4-positive 75-year-old woman, baseline score corresponding to ADAS-Cog 11 of 18, baseline MMSE
score of 23. CIs were obtained via bootstrapping
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approach is focused solely on a memory measure with-
out considering other important areas of cognition af-
fected at early stages of disease and therefore may not
be optimal. The ADAS-Cog 5 combines both approaches
and could theoretically be more sensitive than other var-
iants to detect a change over time. It should be noted
that our goal was not to validate a new instrument.
In the context of this study, we also sought to deter-
mine whether enrichment strategies could improve the
sensitivity to change over time of these ADAS-Cog vari-
ants. Since the introduction of enrichment as part of in-
clusion criteria for early stages of AD in 2007 [21],
enrichment biomarker strategies have been used in clin-
ical trials to include subjects with prodromal AD (also
called MCI due to AD). The enrichment strategy is
aimed at detecting the presence of amyloidosis in the
brain as a hallmark of AD [22, 23], for example by using
CSF biomarkers [24] such as low Aβ and high Tau. As
60 % of subjects with MCI and 40 % of subjects with AD
provided CSF, we used the available CSF baseline data to
select enriched populations (i.e., subjects most resem-
bling those to be recruited into clinical trials). This gave
us the opportunity to also compare the performance of
ADAS-Cog variants in enriched vs. non-enriched
groups. For our analyses, t-Tau/Aβ ratio in the CSF was
used as the primary enrichment strategy to determine
populations with AD pathology (enriched). In addition,
we looked at the impact of single-biomarker modalities
such as Aβ alone, the marker of neurodegeneration Tau
and the prominent genetic risk factor for sporadic AD,
the ApoE4 allele [25]. It should be noted that these are
not defined as enrichment biomarkers in the research
criteria for prodromal AD [16].
There is an increasing body of evidence showing that
AD starts decades before the clinical symptoms become
apparent [26]. With new putative therapies aimed at
slowing disease progression by early intervention, there
is an increasing interest in identifying subjects at early
stages of AD [27]. Advances in the biomarker field allow
us to identify subjects with AD pathology before the
clinical diagnosis is made [28]. It was hypothesised that
using enriched populations in clinical trials reduces vari-
ability and increases the magnitude of cognitive decline
over time, thus reducing the sample size necessary to de-
tect a drug effect in clinical trials [29].
We analysed cognitive decline on the four ADAS-Cog
variants (3-, 5-, 11- and 13-item scales) in ADNI sub-
jects with MCI or mild AD who provided a CSF sample
at baseline. The results showed that, in the MCI popula-
tion, there was a minimal decline over 24 months on all
ADAS-Cog variants. The impact of enrichment was de-
tectable but subtle. The largest decline was less than 3
points over 24 months on ADAS-Cog 13 in enriched
MCI. This provides some support for use of enrichment
as a tool to identify subjects who are more likely to dem-
onstrate a cognitive decline, although, at least in the case
of the MCI, the impact upon such changes measured by
ADAS-Cog variants is minimal and of questionable clin-
ical relevance to be of any practical use for clinical trials
with pharmacological intervention aimed at slowing de-
cline of disease progression.
As expected, decline in mild AD was more pro-
nounced than in MCI but still modest. ADAS-Cog 11
scores of subjects with mild AD declined 3.5 points over
12 months in our analysis. This seems to correspond to
the rate of 2.4 points over 6 months reported by Dorais-
wamy et al. [1]. It should be noted that the rate of de-
cline could be influenced by many factors, such as
education, background medication and potentially attri-
tion. The fact that ADNI participants were highly edu-
cated, with, on average, 15–16 years of education, has
been reported previously [12]. In addition, many ADNI
participants, particularly those with mild AD, may be
receiving symptomatic treatment [30]. Even though
these factors would be of interest, attempting evalu-
ation of all these factors runs the risk that the ultimate
sample size would be too small to provide any mean-
ingful results. The impact of enrichment could not be
evaluated, as over 90 % of subjects with mild AD en-
rolled in ADNI studies had positive AD pathology at
baseline.
These results were also reflected on the MMSE scale:
no worsening in the MCI set and modest worsening in
the mild AD set over time. Meta-analysis of MMSE
change in patients with mild to moderate AD has previ-
ously shown an annual rate of decline of 3.3 points [31].
Similar rates have been reported by other groups [32].
The rate of decline seen in our analysis is more modest,
probably due to the relatively earlier stage of disease
than in previously published studies. It should be noted,
however, that the researchers in the above-mentioned
studies analysed data of non-treated patients, while
many ADNI participants, especially those with mild AD,
were on background medication [30].
The SNR reflects the ratio between mean change and
variability, thus allowing direct comparison of the sensi-
tivity of the different ADAS-Cog variants. High SNR
values reflect increased sensitivity to detect a change
over time, and thus the ADAS-Cog variant with the
highest SNR value should theoretically lead to an opti-
mal instrument.
In MCI, the SNRs for each ADAS-Cog variant and for
each enrichment strategy were relatively similar but low.
The numerically largest SNRs were seen for the ADAS-
Cog 5 and ApoE4 enrichment. However, as the 95 %
confidence intervals around each of the SNRs were
broad, the results did not support a meaningful differ-
ence among groups.
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We confirmed that the ADAS-Cog instrument is not
sensitive to detect change over time at pre-dementia
stages of the disease such as MCI (as shown by small
SNRs), and therefore the impact of enrichment strategies
was subtle. The numerically largest SNR was seen for
the enriched set according to ApoE4 risk. ApoE genotype
is a well-described genetic risk factor for AD associated
with early deficits in episodic recall, higher rates of cog-
nitive decline before the diagnosis of MCI or AD, and
age-related memory decline earlier in life (for review, see
[33]). The presence of an ApoE4 allele doubles the risk
of progression from normal cognition to onset of clinical
symptoms [34]. In addition, the ApoE4 allele has been
associated with a faster cognitive deterioration in several,
but not all, studies of patients with AD. Therefore, ApoE4
genotype is often used as a stratification factor in clinical
trials testing novel therapies and, interestingly, is being
used as an enrichment strategy in the ongoing TOM-
MORROW trial [35]. However, as the 95 % confidence
interval was broad, it can be concluded that the benefit of
such enrichment in MCI seems negligible for this particu-
lar instrument. We do not believe that enrichment would
allow for significant reduction of the required sample size
in MCI if subjects were to be tested using ADAS-Cog.
The SNRs were larger in subjects with mild AD than
in subjects with MCI. Similarly to MCI, the numerically
highest SNRs were generally seen for the ApoE4-
enriched set across all variants. Interestingly, the highest
SNRs were seen for both the 5-item and 13-item ADAS-
Cog variants. This was supported by the p values with
the strongest evidence for a difference seen when com-
paring the 11- vs. 13-item variants and the 3- vs. 5-item
variants. One could speculate that the difference be-
tween variants is driven more by the two additional
items (Delayed Word Recall and Digit Cancellation) than
by removing the items at ceiling in early stages of AD,
suggesting the increase in magnitude of the change out-
weighs the increase in variability.
Limitations of this analysis
In addition to the high education level of ADNI partici-
pants [12, 36] discussed earlier, it is also acknowledged
that the participating sites in the ADNI study are experi-
enced. This is reflected by the observation that there is
less variability in the scores and a more reliable diagno-
sis (>90 % subjects with mild AD had positive AD path-
ology). This is contrary to recent phase III clinical trials
with potential anti-amyloid therapies, which have shown
that enrolling participants without evidence of amyloid
deposition is common [37].
In mild AD, the number of subjects attending follow-
up visits beyond the first year dropped significantly and
did not provide a sufficient number of subjects for
meaningful analyses. Therefore, changes over time
beyond 12 months need to be interpreted with caution.
Per regulatory requirement, a minimum of 18 months of
treatment is required in clinical trials aimed at disease
modification.
It was the purpose of this investigation to analyse sub-
jects with follow-up data. The impact of the clinical
characteristics of subjects who withdrew prematurely on
change over time was not evaluated, as this would have
required assumptions regarding the follow-up data. Such
assumptions are the subject of an ongoing scientific
debate.
We recognize that the value of the ADAS-Cog variants
in our dataset is being judged solely on the basis of a
longitudinal change over time, regardless of the treat-
ment status of included subjects. Therefore, the outcome
may not necessarily directly translate into a variant with
the highest sensitivity to detect differences between
treatments.
It must also be noted that the ADAS-Cog variants
analysed in this study were collected in the context of
ADAS-Cog 11, so the items are likely prone to specific
order effects. Moreover, the 13- and 5-item variants con-
tained additional two items that were tested outside the
original ADAS-Cog 11. The order effect, where exposure
to earlier tests influences performance on later tests, is a
well-known phenomenon in cognitive testing [38].
Conclusions
Whilst the cognitive domain expansion or reduction of
the ADAS-Cog is in principle a worthwhile endeavour,
in practice the use of these measures has been less suc-
cessful. The outcome of our analyses showed that the
possible utility of these novel ADAS-Cog variants is less
than compelling, particularly in MCI. The impact of en-
richment on cognitive decline in MCI using the latest
research criteria [16] was subtle. In mild AD, adding
items known to be impaired at early stages of the disease
seems to provide more benefit than removing items on
which subjects score close to ceiling.
Endnotes
1The text in italics in the Data source section is re-
quired by the ADNI consortium.
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